SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : GUMM - Eliminate the Common Cold
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Street Walker who wrote ()11/2/1999 7:48:00 AM
From: Densiebj  Read Replies (1) of 5582
 
The Study

``This initial clinical research showed that participants who used Zicam(TM) at the onset of symptoms significantly reduced the duration of their colds,' said Dr. Charles B. Hensley, chief of research at Gel Tech, LLC. The double blind placebo-controlled study was conducted by scientists from Gel Tech over a two-cold season period. A total of 104 subjects presenting with at least 3 of 9 cold symptoms for a period of 24 hours or less participated in the study. Patients received a dosage of either the proprietary nasal gel containing the active ingredient or a placebo 4 times daily. Colds were determined to be over when all symptoms were resolved. Subjects receiving the active ingredient found in Zicam(TM) had colds which lasted only 1.5 days on average, while subjects receiving the placebo had colds which lasted 9.8 days on average.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News